Saying "No" To Legislated Disclosure
This article was originally published in RPM Report
Executive Summary
Pharma is being pressed on many fronts to make its promotional and educational spending public. One of the biggest threats comes from Congress, where Sen. Grassley would like to make full disclosure mandatory. Voluntary disclosure by companies and new rules on gifts by professional societies may be enough to stave off Congressional action this year.
You may also be interested in...
Grassley pushes universities for transparency
Officials at academic research institutions are the latest group to feel pressure from Sen. Chuck Grassley, R-Iowa, who is looking to shed light on drug companies' financial ties to researchers. The ranking Republican on the Senate Finance Committee sent letters to leaders of almost two dozen universities asking them to examine their conflict of interest and financial disclosure policies. Grassley says he is concerned that drug company funding can influence scientific studies and that university faculty do not always report their outside income. Grassley previously prodded NIH director Elias Zerhouni to review his agency's oversight of outside grant recipients' conflicts of interest (1"The Pink Sheet," June 30, 2008, In Brief)
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way
Flourishing In the Sunshine: Disclosure as a new Commercial Advantage
Orthopedic device manufacturers are out ahead of the drug industry in adapting to new payment disclosure laws. One company, Stryker, has embraced the requirement wholeheartedly and may have found a way to make the listing a benefit to doctors and patients.